and oligomers as well as their effect on site-specific tau phosphorylation in this transgenic mouse model. Our observations suggest that the different human A ␤ isoforms do not directly cause increased tau phosphorylation and that the cognitive deficits seen in this mouse model are only related to the A ␤ overexpression.
cies [3] . Several different soluble oligomeric species, ranging from 8 kDa to over 100 kDa, occurring under the A ␤ fibrillization process have been identified, including dimers, A ␤ -derived diffusible ligands, A ␤ * 56, globulomers and protofibrils [4] [5] [6] [7] [8] [9] .
It is also evident that hyperphosphorylation of tau is tightly linked to the neurodegenerative process in AD. The protein kinases cdk5 and GSK3 ␤ have been suggested to be central players in tau phosphorylation [10] , while a number of other protein kinases, including mitogenactivated extracellular signal-regulated protein kinases (MAPK/ERKs), stress-activated protein kinases (SAPK/ JNKs) and p38 also contribute [11] [12] [13] . Among various protein phosphatases, PP1, PP2A, PP2B and PP5 have been shown to dephosphorylate tau [9] . Interestingly, studies have shown that the severity of cognitive impairment correlates better with the amount of NFTs than with the amount of A ␤ plaques [14] .
Tg2576 mice overexpressing the mutant form of amyloid precursor protein (APP) are well characterized regarding A ␤ pathology and cognition. They display an age-dependent increase in A ␤ 40 and A ␤ 42, resulting in thioflavin-S-positive plaques similar to those found in AD, along with gliosis and dystrophic neurites but no NFTs or neuronal loss [15, 16] . The mice show deficits in cognitive testing, which have been considered to be the result of A ␤ pathology. In an earlier study where we investigated the development of A ␤ pathology and its consequences, we observed that the Tg2576 mice display increased levels of total membrane-bound APP compared to nontransgenic controls as well as an age-dependent increase in the levels of human sAPP ␣ [17] . In addition, we found high Tris-soluble A ␤ 1-40 at 7 days of age compared to older ages while there was no differences in the guanidinium-soluble A ␤ 1-40 or A ␤ 1-42 [17] . Furthermore, we have shown an age-dependent shift in the A ␤ pattern of the brain; brains from older mice contained more A ␤ 1-40 and less A ␤ 1-17 than younger animals [18] .
Since the soluble A ␤ oligomers have been considered the most toxic species, we analyzed the temporal relationship between different A ␤ isoforms and soluble oligomers on tau phosphorylation in the cortex of Tg2576 mouse model between the ages of 7 days and 15 months. Young animals (ages 7-90 days) displayed high levels of the shorter A ␤ isoforms, A ␤ 1-16 and A ␤ 1-17, which is in agreement with the previous study [18] . The longer and more fibrillogenic A ␤ 1-42 showed an age-dependent increase, whereas total A ␤ 1-40 levels remained quite constant throughout the ages investigated. In the TBS fraction, we observed high levels of several soluble oligomeric species of A ␤ at 90 days of age. Judging from this study, it appears as if human A ␤ is not sufficient to cause increased tau phosphorylation in these mice. These observations are important; since they suggest that the different human A ␤ isoforms do not directly cause increased phosphorylation of tau and that the cognitive deficits seen in these mice are probably only linked to the A ␤ overexpression in this mouse model.
Materials and Methods

Transgenic Animals
The principles of laboratory animal care (1996 NIH Revised Guide for the Care and Use of Laboratory Animals) were followed. All animal experimental protocols were approved by the local ethics committee and carried out in accordance with the guidelines of the Swedish National Board for Laboratory Animals (Dnr S81/01, S129/04).
Tg2576 mice [19] were obtained and handled as previously described [17] . The Tg2576 mice and age-matched nontransgenic littermates were used at the following ages: 7 days (6 U Tg+ and 6 U Tg-), 21 days (6 U Tg+ and 6 U Tg-), 3 months (6 U Tg+ and 6 U Tg-) and 15 months (3 U , 2 -Tg+ and 6 U Tg-). It is known that after 12 months of age the viability of mice drastically decreases. In our 15 month-old group, several of our female mice died of old age. Therefore, we had to add 2 male mice in this group to keep the numbers to obtain statistical significance between the groups. Different authors have demonstrated differences between males and females in mice [20] [21] [22] . However, we could not observe any outliers in the transgenic group at 15 months of age in our data regarding the A ␤ levels, which indicates that in our study there were no differences between males and females. The mice were killed by decapitation, and the brains were quickly removed and cut in half sagittally; half of the brain was dissected, frozen on dry ice and maintained at -80 ° C.
Tissue Preparation
Homogenates were prepared from the dissected cortices with ice-cold homogenate buffer [containing 50 m M Tris, 1 m M EGTA and EDTA, protease inhibitor cocktail (Sigma), phosphatase inhibitor 1 and 2 (Sigma), sodium butyrate and PMSF] and centrifuged at 16,000 g at 4 ° C for 30 min. The supernatants were used for A ␤ ELISA and Western blot analysis. A DC protein assay kit (Bio-Rad) was used to measure the protein content of the fractions.
A ␤ Extraction for MALDI-TOF MS
The second brain hemisphere was dissected, and the cortices (30-80 mg) were homogenized (Pellet Pestle, Sigma-Aldrich, St. Louis, Mo., USA) on ice in Tris-buffered saline (20 m M Tris, 137 m M NaCl, pH 7.6) with complete protease inhibitor tablets (Roche, Basel, Switzerland). The extraction ratio (brain tissue:TBS) was 1: 5 (w/v). Formic acid (FA) was added to the sample (final concentration 70%) followed by sonication (power: 15 amplitude microns; tune: 'middle') and centrifugation at 30,000 g for 1 h at 4 ° C. The FA-soluble A ␤ extract was dried and dissolved in FA, and finally neutralized using 0.5 M Tris.
Immunoprecipitation and Mass Spectrometry
IP using the KingFisher magnetic particle processor (ThermoScientific, Waltman, Mass., USA) and mass spectrometric analysis using MALDI-TOF MS were performed as described earlier [23] . Briefly, an aliquot (8 g) of the anti-A ␤ antibodies 6E10 and 4G8 (Signet Laboratories, Dedham, Mass., USA), which is reactive to amino acids 1-17 and 17-24, respectively, was separately added to 50 l each of magnetic Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen, Carlsbad, Calif., USA). The 6E10 and 4G8 antibodycoated beads were mixed and added to 5-10 l brain homogenate, and diluted to 1 ml in 0.025% Tween 20 in phosphate-buffered saline (pH 7.4). After washing, using the KingFisher magnetic particle processor, the A ␤ isoforms were eluted using 100 l 0.5% FA. MALDI-TOF MS measurements were performed using an Autoflexinstrument (Bruker Daltonics, Bremen, Germany) operating in linear mode at 19 kV acceleration voltages. Each spectrum represents an average of 1,500 shots acquired 75 at a time. The MAL-DI samples were prepared with the seed layer method using ␣ -cyano-4-hydroxycinnamic acid as the matrix. Each isoform in the spectra was normalized to the sum of all isoforms in the spectra. This kind of data shows the relative changes of all the different isoforms in response to age. It should be noted that the ratio between the different isoforms detected in the mass spectrum cannot be interpreted as a direct reflection of their absolute or relative abundance in the brain since the ionization efficiency might be different for the different isoforms and since different isoforms are more hydrophobic and less soluble than others.
Western Blots
The samples (20 g/well) were loaded on 26-well 10-20% TrisHCl Criterion gels (BioRad, Sundbyberg, Sweden). Due to the number of samples, they were divided into two different gels. Both gels were then run at the same time in the same tank and transferred to PVDF membrane by using the iBlot Dry Blotting system (Invitrogen, Paisley, UK) at 20 V for 7 min. The membranes were dried in methanol and then completely rehydrated in 20 m M Tris Base Sodium-Tween (TBS-T) 0.1%, pH 7.4. For phospho-tau, phospho-GSK-3 ␤ , Cdk5 and p25/p35 antibodies, nonspecific binding sites were blocked with 5% bovine serum albumin (BSA) or 5% non-fat dry milk in TBS-T buffer for 1 h at room temperature. The blots were then incubated with primary antibodies at appropriate concentrations ( table 1 ) diluted in 1-5% BSA in TBS-T 0.1% overnight at 4 ° C with mild agitation followed by the appropriate HRPconjugated secondary antibodies (goat anti-rabbit or goat antimouse, Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA) diluted in 1-5% BSA in TBS-T 0.1% buffer for 1 h. Next, all membranes were washed with TBS-T washing buffer three times (5 min each time) with mild agitation. The blots were then incubated with ECL reagents (GE Healthcare, Uppsala, Sweden), exposed and developed in a CCD camera using LAS Image 3000. The membranes were then stripped with stripping buffer [50 m M Tris (pH 6.8), 2% SDS and 10 m M BME] for 20 min at 55 ° C with mild agitation, followed by washing with TBS-T buffer (3 ! 5 min). The membranes were then blocked again according to the procedure above and probed with primary antibodies against total tau or total GSK-3 ␤ followed by incubation with appropriate secondary antibodies, and washing (3 ! 5 min with TBS-T washing buffer). The blots were then incubated with ECL reagents (GE Healthcare, Uppsala, Sweden), exposed and developed as before. The blots were then stripped again with stripping buffer for 20 min at 55 ° C with mild agitation, followed by washing with TBS-T buffer (3 ! 5 min). The membranes were then blocked according to the procedure above and probed with primary antibodies against ␤ -actin followed by incubation with secondary antibody goat-anti-mouse, and washing (3 ! 5 min with TBS-T washing buffer). The blots were then incubated with ECL reagents (GE Healthcare, Uppsala, Sweden) and exposed and developed as before.
For A ␤ , the cortical TBS fraction of the transgenic mice (15 g protein/well) was loaded on 26-well 10-20% Tris-Tricine Criterion gels (BioRad) and transferred to PVDF membrane by using the iBlotf Dry Blotting system (Invitrogen, Paisley, UK) at 15 V for 6 min. Nonspecific binding sites were blocked with 5% BSA TBS-T buffer for 1 h at room temperature. The blots were then incubated with primary antibodies 82E1 (Immuno-Biological Laboratories Co., Ltd, Japan) or NU-4 (kind gift from Drs. Klein and Lacor [24] ) diluted 1: 1,000 in 5% BSA in TBS-T 0.1% overnight at 4 ° C with mild agitation followed by the goat anti-mouse 1: 3,000 (Santa Cruz Biotechnology) diluted in 5% BSA in TBS-T 0.1% buffer for 1 h. The blots were then incubated with ECL reagents (GE Healthcare, Uppsala, Sweden), exposed and developed as before followed by stripping and probing with primary antibodies against ␤ -actin according to the procedures above and developed according to the procedures above. The current A ␤ antibodies are not specific for low-n oligomers and antibodies that can reliably detect large A ␤ oligomers may also detect other non-A ␤ proteins. The 82E1 antibody has been well characterized as human A ␤ N-terminal specific. It reacts with both soluble and fibrillar A ␤ to a similar degree and does not cross-react with mouse A ␤ [25] . The creators of the NU-4 antibody suggest that the NU-4 epitope is three-dimensional, in which aggregation of A ␤ 1-28 to form a dimer is necessary to align correct amino acids in the binding pocket, perhaps several from each single peptide. The specificity of the NU-4 antibody includes lower order and prominent higher order oligomers (12-24-mers) but not monomers [24] .
Image Analysis of Western Blots
Western blot images were analyzed as previously described [26] . In short, the optical densities (ODs) of each band were measured using Image J program (version 1.38x). Values are reported as the product of the contour OD and contour area, with subtraction for the background. First the ␤ -actin band was analyzed to confirm loading consistency. Then, an immunoreactivity ratio was obtained by normalizing the OD from the phospho-protein against that of the corresponding total protein. For Cdk5, p35 and p25, the ␤ -actin was analyzed to confirm loading consistency, and then the band for each antibody and gel was analyzed.
Statistical Analysis
All data are presented as mean 8 SEM. All results were analyzed using the nonparametric Kruskal-Wallis test, followed by the Mann-Whitney post-hoc test. 
Results
A ␤ Isoforms in the Cortex of Tg2576 Mice
The whole cortex of 4 age groups with 3-6 mice in each group was analyzed using IP-MS. Seven different peaks at different mass-to-charge ratios (m/z) were reproducibly detected, which by mass were assigned to be 7 isoforms of A ␤ (A ␤ 1-16, A ␤ 1-17, A ␤ 1-37, A ␤ 1-38, A ␤ 1-39, A ␤ 1-40 and A ␤ 1-42). As previously reported, A ␤ 1-40 was the most abundant isoform in the cortex of the Tg2576 mice, with high levels already at 7 days of age followed by fairly unchanged levels throughout the ages investigated here ( fig. 1 ) . In contrast, A ␤ 1-42, which is more prone to aggregate than A ␤ 1-40, increased with age. Interestingly, the data revealed an age-dependent shift in the A ␤ pattern; brains of older Tg2576 mice contained more of the longer A ␤ 1-42 and much less of the shorter A ␤ 1-16 and A ␤ 1-17 than the younger animals ( fig. 1 ) .
TBS Fraction Oligomeric A ␤
To further explore the species involved, we utilized Western blot using antibodies 82E1 and NU-4. The 82E1 is a human-specific N-terminal end-specific A ␤ antibody, while the NU-4 recognizes lower order and prominent higher order oligomers (12-24-mers). We obtained similar bands for both antibodies; the only differences being the very faint bands for lower molecular weight tetramers, trimers, dimers and monomers for 82E1, not visible using the NU-4 antibody. However, the bands were too weak to analyze, and therefore we analyzed pentamers and higher order oligomers for the two antibodies. We found similar results for both antibodies, and therefore only the results of the NU-4 antibody are shown ( fig. 2 ) . The highest levels of A ␤ oligomers were found at 90 days of age ( fig. 2 ) . Another interesting observation was that the levels of oligomers lower than 26-mers were reduced in 15-month-old animals compared to 90-day-old mice, probably due to the increased fibrillization and aggregation in the older mice ( fig. 2 ). 
Tau Phosphorylation
We observed increased absolute levels of total tau and phosphorylated tau at Ser 396 , Ser 404 and Ser 422 at 7 days of age in both Tg2576 mice and nontransgenic controls compared to older ages. However, when correcting for the levels of total tau, there were no significant differences in tau phosphorylation in Tg2576 mice or nontransgenic controls at any of the epitopes studied, except at Ser 422 , where we observed a reduction at 7 days of age compared to age-matched nontransgenic controls ( fig. 3 a-d) . For the phospho-tau Ser 396 antibody, we observed an additional band at ϳ 70 kDa, indicative for a cross-reaction with some other mouse brain protein. This band was not analyzed.
GSK3 ␤
We observed significantly increased levels of phosphorylated GSK3 ␤ (P-Ser 9 and Y216) in 7-day-old Tg2576 mice compared with nontransgenic controls ( fig. 4 ). There were no differences at any other time point. Normalized intensity expressed for total tau ( a ) and as the ratio between phosphorylated tau (AT8)/total tau (Tau5) ( b ), (Ser 396 )/total tau (Tau5) ( c ), (Ser 404 )/total tau (Tau5) ( d ) and (Ser 422 )/total tau (Tau5) ( e ) in the cortex of Tg2576 transgenic mice and nontransgenic controls at 7 days to 15 months. f Representative blots. * p ! 0.05 indicates significant difference between Tg2576 mice and age-matched controls; a p ! 0.05 and aa p ! 0.01 represent significant differences between 7-day-old mice and 21-day-old or 15-month-old mice; b p ! 0.05 indicate significant difference between 21-day-old and 15-month-old mice; c p ! 0.05 indicate significant difference between 90-day-old mice and 15-month-old mice. Values are expressed as mean 8 SEM.
Cdk5, p35 and p25
To further investigate if the changes in tau phosphorylation might be due to cdk5, we investigated the levels of this kinase in addition to those of its activators p35 and p25. We found significantly reduced levels of cdk5 at 7 days of age in Tg2576 mice compared with age-matched nontransgenic controls ( fig. 5 a) .
In addition, there were decreased levels of p35 at 90 days in Tg2576 mice compared with age-matched nontransgenic controls ( fig. 5 c) . Interestingly, we also observed a reduction in p25 levels at 7 days in Tg2576 mice compared to nontransgenic controls, followed by an increase at 15 months of age ( fig. 5 b) .
Discussion
The possibility of using a combination of mass spectroscopy and Western blots allowed us to investigate the effect of different A ␤ isoforms and oligomers on tau phosphorylation. There is evidence that the pathological changes seen in AD patients are ongoing for decades before symptoms become manifest. Patients with mild cognitive impairment that subsequently convert to AD have shown high amyloid load in the brain as visualized by 11 C-PIB positron emission tomography imaging as well as low levels of A ␤ 42 and high levels of tau and phosphorylated tau at threonine 181 in the cerebrospinal fluid [27, 28] . The mechanisms disrupting cognitive function in AD are not completely understood, and it is difficult to address this problem in human patients. Therefore, animal models are needed to elucidate the possible disease mechanisms.
We have shown earlier that the Tg2576 mice have an age-dependent increase in total membrane-bound APP as well as human sAPP ␣ [17] . In addition, they display high Tris-soluble A ␤ 1-40 at 7 days of age compared to older ages, while there was no differences in guanidinium-soluble (insoluble) A ␤ 1-40 or A ␤ 1-42 [17] . In the present study, MALDI-TOF MS measurement of cortical A ␤ revealed that A ␤ 1-40 is the most abundant isoform in the Tg2576 mice. We also observed an age-dependent shift in the A ␤ pattern; the older Tg2576 mice produced more of the longer A ␤ 1-42 and much less of the shorter A ␤ 1-16 and A ␤ 1-17 than the younger animals, which is in agreement with earlier findings in these mice [18] . It is an established fact that the Tg2576 mice display an age-dependent increase in A ␤ 40 and A ␤ 42, resulting in thioflavin-S-positive plaques similar to those found in AD. The plaques, consisting mainly of A ␤ 40, are first clearly seen by 11-13 months and eventually become widespread in cortical and limbic structures. Earlier, the plaques were considered to be neurotoxic, but the focus has now shifted towards the formation of soluble A ␤ oligomers, which have repeatedly been reported to contribute significantly to the pathophysiological alterations underlying AD. Furthermore, soluble oligomeric A ␤ 42 and not plaque-associated A ␤ correlate best with cognitive dysfunction [29, 30] . Therefore, we used Western blot to investigate in detail the TBS-soluble oligomeric assemblies of A ␤ in the cortex of these mice. The highest levels of the different soluble oligomers studied could be observed at 90 days of age. These findings might be interpreted as age-dependent aggregation of A ␤ into larger assemblies, which fits well with the age-dependent increase in brain total A ␤ 1-42 as detected by IP-MS.
Taken together, the shifts from the shorter A ␤ 1-16 and A ␤ 1-17 at younger ages to the longer A ␤ 1-42 at 15 months of age as well as the changes in soluble oligomeric A ␤ are the most significant findings in this study. It is a well-known fact that the 56-kDa soluble oligomer does not appear until 6 months of age in the Tg2576 brain [6, 31] . Interestingly, by using the 82E1 and NU-4 antibodies we observed a 56-kDa band already at 7 days of age, which might suggest that this dodecamer is present in this mouse model earlier than previously reported. Further studies are needed to determine if the 56-kDa soluble oligomer influences the brain development in these mice.
In AD, tau protein becomes hyperphosphorylated, although the mechanism by which tau exerts its neuronal toxicity is still controversial [32] . Several lines of evidence suggest that in the AD brain, tau pathology occurs downstream of A ␤ accumulation. Soluble A ␤ has been shown to form complexes with tau, and this might have implications for the development of AD [33] . In addition, A ␤ ac- tivates GSK3 ␤ , and thereby triggers tau phosphorylation [34] . The results of recent studies suggest that the functional impacts of tau phosphorylation depend on the specific phosphorylation sites and the extent of phosphorylation [35, 36] . The phosphorylation state of tau is controlled by a balance in the activities of different kinases and phosphatases. The large number of different phospho-tau epitopes has made it difficult to ascertain the precise role of each form in disease development and progression. We used the Tg2576 transgenic mice to study the local relationship between A ␤ and tau phosphorylation at a total of 6 phosphorylation sites. We observed an increase in absolute levels of both total tau and phospho- tau at 7 days of age in both Tg2576 mice and nontransgenic controls. Since there was no difference between Tg2576 mice and nontransgenic controls, this finding is most likely a part of the normal development of the brain. Animal studies suggest that phosphorylation of tau is a physiological way of destabilizing axons in the developing brain, promoting synaptic plasticity [37] . However, when correcting for the levels of total tau, there were no significant differences in tau phosphorylation in Tg2576 mice or nontransgenic controls at any of the epitopes studied, except at Ser 422 , where we observed a reduction at 7 days of age compared to age-matched nontransgenic controls. The decrease in overall tau phosphorylation in adult brain might be due to the higher levels of tau phosphatases in mature brain. However, this needs to be further evaluated.
Our results suggest that although in the presence of human A ␤ in Tg2576 mice, there is no increase in the phosphorylation of tau at the sites studied. Whether this depends on the differences between mouse and human tau or if it is an indication that A ␤ alone is not sufficient to induce neurofibrillary changes, subsequently leading to the full extent of AD pathology, remains to be elucidated. In this study, the smaller oligomers (pentamers, hexamers and heptamers) all showed a significant positive correlation with tau phosphorylation at AT8 and Ser 396 ( fig. 6 ). Does the temporal correlation of these isoforms on tau phosphorylation indicate a first sign of AD pathology or could it be a developmental effect that is not found in normal development? The correlations might have several different explanations: (1) they might indicate a first sign of AD pathology; (2) mouse tau does not react similar to human tau to these oligomers; (3) certain pathological features in the human brain might be missing in the mouse brain, and therefore (although the A ␤ oligomers correlate with increased tau phosphorylation) the pathology cannot proceed and develop into hyperphosphorylation of tau and NFTs; (4) a developmental effect in the brain of these mice not normally found. However, addressing this fully would be a whole study in its own right and is beyond the scope of this study.
GSK3 ␤ phosphorylates tau at several phosphorylation sites. It is well established that phosphorylation at Tyr 216 is required for the kinase to be activated, while it is inactivated by phosphorylation at Ser 9 [38, 39] . We observed increased phosphorylation at both Tyr 216 and Ser 9 in 7-day-old Tg2576 mice compared to nontransgenic controls. This is in line with previous data where APPV717I transgenic mice have an increased phosphorylation at Tyr 216 on GSK-3 ␤ , leading to an increase in tau phosphorylation at Ser 396/404 [34] . It is tempting to suggest that the increased phosphorylation of GSK-3 ␤ Ser 9 (the major regulating mechanism of GSK3 ␤ activity) might counteract the activation of GSK3 ␤ , leading to no change in tau phosphorylation. At later ages, there were no differences in GSK3A activity in Tg2576 mice compared to nontransgenic controls, indicating that A ␤ does not activate GSK3 to a greater extent in this mouse model.
The Cdk5 is one of the major players in the phosphorylation of tau in AD, while p35 is known to be one of the major cdk5 activator proteins. Inhibition of cdk5 activity increases the stability of p35 [40] . Dysregulation of cdk5 activity by cleavage of p35 to p25 by calpain is associated with pathological degeneration of neurons. Therefore, the levels of cdk5, p35 as well as p25 were investigated. At 7 days of age, there was a reduction in the levels of p25 in the Tg2576 mice compared to nontransgenic control. At 15 months of age, there was a decrease in p25 levels in the nontransgenic controls, while it remained higher in Tg2576 mice at the same age. The high levels in Tg2576 mice might be caused by the prolonged A ␤ exposure of the cells, since studies have shown that the conversion from p35 to p25 occurs in the presence of various neuronal insults, such as excitotoxic glutamate, hydrogen superoxide H 2 O 2 , or A ␤ peptides [41] .
It is important to remember that the pathological significance of changes occurring at 7 and 21 days should be evaluated with caution. At these ages, the brain is still developing, and the ongoing processes might be very different compared to the changes occurring in a more mature brain (90 days and 15 months of age).
In conclusion, this study shows that the Tg2576 mice express a variety of A ␤ isoforms, among them the two major species important in AD, A ␤ 1-40 and A ␤ 1-42. The shift in the A ␤ pattern observed in Tg2576 mice during aging, from the shorter A ␤ 1-16 and A ␤ 1-17 to the longer A ␤ 1-42, might be one of the initiating factors for A ␤ deposition in the brain. As reported earlier, there is no apparent change in tau phosphorylation in Tg2576 mice compared to nontransgenic controls, which indicates that A ␤ alone is not enough to cause hyperphosphorylation of tau and subsequent tau pathology. However, the correlation between shorter soluble oligomeric forms and increased tau phosphorylation may provide a link between A ␤ and tau. The fact that these mice do not exhibit significant neuronal loss or the inflammatory changes seen in AD further underlines the differences between transgenic models and human patients, making it more difficult to correctly interpret the data.
This study reveals new information about the A ␤ pathology in the brain of Tg2576 mice, indicating that the neuropathological changes in these mice are ongoing long before the actual appearance of the hallmarks of the disease. It has enlightened our view with regard to the different forms of A ␤ and their consequences on tau phosphorylation in the brain which might be of great importance for developing future disease-modifying therapies.
